CTIM-76 Shows 22% ORR in Platinum-Resistant Ovarian Cancer as Cash Runs to Early Q4 2027
CNTX is trading near its 52-week low of $0.18 (4.2% above the low).
Summary
Context reported Q3 2026 results alongside longer-term Phase 1 data for CTIM-76, its CLDN6 x CD3 T cell engager. In nine efficacy-evaluable platinum-resistant ovarian cancer patients dosed weekly at 140–280 µg, confirmed ORR was 22% and DCR 56%, with median PFS of 5.6 months — a meaningful benchmark given patients had a median of six prior lines of therapy and 80% had prior ADC exposure. Liver metastases responded too: all seven target lesions shrank, two disappearing entirely. Safety was manageable at active doses, with Grade 1/2 CRS in 18.5% of 27 patients and dose-related Grade ≥3 liver enzyme elevations that resolved on continued dosing. Cash of $34.4M at September 30 funds operations into early Q4 2027, and the company guided to Phase 1b initiation in Q1 2027 with initial every-three-week efficacy data in Q2 2027. The Q3 net loss narrowed to $7.6M from $9.7M a year ago on lower CT-202 spending. The stock trades near its 52-week low, so the data readout and runway extension are the two things that matter here.
At the time of this announcement, CNTX was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.2M. The 52-week trading range was $0.18 to $3.62. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.